Terms: = Pancreatic cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
103 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With pancreatic cancer Treated With Perioperative Adjuvant Chemotherapy.
Kawahara S; Aoyama T; Murakawa M; Kanemoto R; Takahashi D; Kamioka Y; Hashimoto I; Maezawa Y; Kobayashi S; Ueno M; Yamamoto N; Oshima T; Yukawa N; Rino Y; Saito A; Morinaga S
Anticancer Res; 2024 Apr; 44(4):1711-1718. PubMed ID: 38537971
[TBL] [Abstract] [Full Text] [Related]
3. Near complete remission of an inoperable pancreatic acinar cell carcinoma after braf-/MEK-inhibitor treatment-A case report and review of the literature.
von Fritsch L; von Bubnoff N; Weber K; Kirfel J; Schreiber C; Keck T; Wellner U
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23222. PubMed ID: 38340027
[TBL] [Abstract] [Full Text] [Related]
4. Ex vivo modeling of acquired drug resistance in braf - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.
Steiner S; Pliego-Mendieta A; Haberecker M; Hussung S; Kollár A; Fritsch R; Arnold F; Lenggenhager D; Planas-Paz L; Pauli C
Cancer Lett; 2024 Mar; 584():216650. PubMed ID: 38246222
[TBL] [Abstract] [Full Text] [Related]
5. RNF43 Inactivation Enhances the b-raf/MEK Signaling and Creates a Combinatory Therapeutic Target in cancer Cells.
Hsu SH; Tsai YL; Wang YT; Shen CH; Hung YH; Chen LT; Hung WC
Adv Sci (Weinh); 2024 Mar; 11(12):e2304820. PubMed ID: 38225722
[TBL] [Abstract] [Full Text] [Related]
6. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
7. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
8. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
[TBL] [Abstract] [Full Text] [Related]
9. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
10. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable braf V600E mutant colorectal oligometastases.
Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T
BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122
[TBL] [Abstract] [Full Text] [Related]
11. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
12. Targeted Therapy for braf V600E Positive pancreatic Adenocarcinoma: Two Case Reports.
Shah S; Rana T; Kancharla P; Monga D
Cancer Genomics Proteomics; 2023; 20(4):398-403. PubMed ID: 37400141
[TBL] [Abstract] [Full Text] [Related]
13. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
[TBL] [Abstract] [Full Text] [Related]
14. Comparative Genomic Analysis of pancreatic Acinar Cell Carcinoma (PACC) and pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
[TBL] [Abstract] [Full Text] [Related]
15. Impact of KRAS and braf mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract] [Full Text] [Related]
16. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.
Ye TW; Wang DD; Lu WF; Xie YM; Xu FQ; Fu TW; Zhang KJ; Liu SY; Xie GL; Cheng J; Jiang K; Xiao ZQ; Yao WF; Shen GL; Liu JW; Huang DS; Zhang CW; Liang L
Expert Rev Gastroenterol Hepatol; 2023 Apr; 17(4):395-403. PubMed ID: 36939280
[TBL] [Abstract] [Full Text] [Related]
17. Advances in the treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
Garcia-Carbonero R; Anton-Pascual B; Modrego A; Del Carmen Riesco-Martinez M; Lens-Pardo A; Carretero-Puche C; Rubio-Cuesta B; Soldevilla B
Endocr Rev; 2023 Jul; 44(4):724-736. PubMed ID: 36879384
[TBL] [Abstract] [Full Text] [Related]
18. α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death.
Abuasaker B; Garrido E; Vilaplana M; Gómez-Zepeda JD; Brun S; Garcia-Cajide M; Mauvezin C; Jaumot M; Pujol MD; Rubio-Martínez J; Agell N
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614192
[TBL] [Abstract] [Full Text] [Related]
19. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract] [Full Text] [Related]
20. Oncological management dilemma: a rare presentation of hairy cell leukaemia with hepatic involvement presenting concomitantly with pancreatic adenocarcinoma.
Al-Saheli ZI; Bazzi T; Barthel B
BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36414341
[TBL] [Abstract] [Full Text] [Related]
[Next]
